Incidence of MACE in Patients Treated With CAR-T Cell Therapy
2023; Elsevier BV; Volume: 5; Issue: 6 Linguagem: Inglês
10.1016/j.jaccao.2023.07.009
ISSN2666-0873
AutoresBénédicte Lefebvre, Yu Kang, Azin Vakilpour, Takeshi Onoue, Noelle V. Frey, Priya Brahmbhatt, Brian Huang, Kemi Oladuja, Daniel Koropeckyj-Cox, Courteney Wiredu, Amanda M. Smith, Jesse Chittams, Joseph R. Carver, Marielle Scherrer‐Crosbie,
Tópico(s)Advancements in Semiconductor Devices and Circuit Design
ResumoPrevious retrospective studies have shown that chimeric antigen receptor T (CAR-T) cell therapy may be associated with major adverse cardiovascular events (MACE), especially in the context of cytokine-release syndrome (CRS) events.
Referência(s)